Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GO-VIBRANT: Golimumab IV in Active Psoriatic Arthritis
NCT02181673Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2014
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Placebo -> Golimumab with Golimumab (2 arms). Primary endpoint: American College of Rheumatology 20% Response at 14 weeks. Started Sep 2014; status: completed.
02
Drugs
golimumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02181673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02181673.